Engineering and Development

Management and Executive

Legal and Compliance

Sales

Chief Operating Officer

H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

Halozyme price target raised by $2 at JPMorgan, here's why

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Specialty Account Manager

Halozyme, Inc. is dedicated to reinventing the patient experience and advancing drug delivery. As a Specialty Account Manager, you will drive new prescriptions for Halozyme products by educating and influencing targeted specialties, while maintaining knowledge of managed care insurance plans and reimbursement policies.

Specialty Account Manager - Pasadena, CA

Director Talent Acquisition

Senior Specialty Account Manager

Sign up with Google

Sign in with Google